Last reviewed · How we verify
Clobetasol Propionate cream treatment
Clobetasol Propionate cream, marketed by University Hospital, Rouen, is a topical corticosteroid with a well-established presence in the dermatological segment. The key composition patent is set to expire in 2028, providing a significant period of market exclusivity and potential revenue protection. However, the lack of reported primary trial results and revenue data poses a risk in assessing the drug's current market performance and competitive landscape.
At a glance
| Generic name | Clobetasol Propionate cream treatment |
|---|---|
| Also known as | DERMOVAL or CLARELUX cream |
| Sponsor | University Hospital, Rouen |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of Bullous Pemphigoid With Avdoralimab (IPH5401), an Anti-C5aR1 Monoclonal Antibody (PHASE2)
- Clinical Trial to Demonstrate That the Dual Laser Therapy is Effective for the Treatment of Vulvar Lichen Sclerosus (NA)
- Evaluation of Fluid Retention Due to Superpotent Topical Corticosteroid (PHASE4)
- Laser vs Clobetasol for Lichen Sclerosus (PHASE3)
- Treatment of Vulvar Lichen Sclerosus With Corticosteroid Ointment, Calcineurin Inhibitor Ointment, and Platelet-Rich Plasma (PRP) Therapy. (NA)
- Phase II Study Evaluating the Clinical Efficacy and Safety of GN-037 in Plaque Psoriasis (PHASE2)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Influence of Dermocorticoids on Bone Mineral Density in Patients With Bullous Pemphigoid (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: